Radio-labelled fibroblast activation protein inhibitors in interstitial lung diseases – a systematic review

An increasing body of evidence supports that FAPI tracers hold great clinical potential for the management of ILD by accurately monitoring fibrotic disease activity and identifying patients at risk of progression. Further research is required to confirm these findings.